Cohance Lifesciences Ltd Q1 FY27 Results Analysis: Revenue Plunges 23%, EBITDA Margin Collapses

Cohance Lifesciences Ltd's Q1 FY27 numbers came in soft. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

COHANCE reported a weak Q1 with revenue down 23% YoY and EBITDA margin collapsing to near zero. The balance sheet remains strong with net cash of Rs.251 Cr and free cash flow generation of Rs.106 Cr, but the operating performance is severely challenged. Management expects a recovery from H2 driven by Sapala growth and pipeline, but the deep revenue hole makes this a high bar.

Key Investment Insights

Key Positives

• Sapala (oligonucleotides) revenue grew 2.5x YoY, becoming a new growth driver from global innovators
• Free cash flow of Rs.106.3 Cr generated in Q1 despite operating loss, reflecting working capital release
• Net cash position improved by Rs.98.5 Cr to Rs.251.2 Cr from Rs.152.7 Cr at FY26 year-end
• Net working capital days improved to 141 from 154 at FY26, driven by reduction in trade receivables

Risk Factors

• Consolidated revenue declined 23.1% YoY to Rs.422.26 Cr, with broad-based weakness across segments
• EBITDA (Reported) margin collapsed to 0.3% from 20.4% a year ago, a compression of 2,010 bps
• PAT swung from profit of Rs.46.40 Cr to loss of Rs.45.19 Cr, a deterioration of Rs.91.59 Cr
• NJ Bio subsidiary EBITDA loss of Rs.32.8 Cr dragged consolidated results, with NCI loss widening to Rs.21.07 Cr
• Specialty Chemicals revenue declined 34.7% YoY, indicating headwinds in AgChem
• CFO transition with resignation effective Sep 13, 2026, and no successor named yet